Determination of circulating amyloid precursor protein in diagnosis and monitoring of disease progression in systemic amyloidosis

V.V. Rameev, MD; L.V. Kozlovskaya, MD, PhD, Prof; E.A. Malinina, A.G. Serova, I.N. Kogarko, MD, PhD; B.S. Kogarko, MD, PhD; N.V. Liubimova, MD, PhD

I.M. Sechenov Moscow Medical Academy; Chemistry and Physics Research Institute of Russian Academy of Sciences; Research Center of Oncology of Russian Academy of Medical Sciences
Serum amyloid A (SAA) plasma level was measured at 43 patients with chronic inflammatory diseases, including 31 patients with reactive AA-amyloidosis and 12 patients not having amyloidosis (control group). SAA-protein concentration was measured with immune-enzyme analysis (ELISA) in laboratory, corresponding to European standards. The level of immunoglobulin light chains was measured at 31 patients with AL-amyloidosis. Low plasma concentration of immunoglobulin light chains, detected with Freelite method, or its decrease after treatment, indicates relatively favorable prognosis. In contrast, high plasma level of immunoglobulin light chains show very unfavorable outcome. Increase of SAA plasma level indicates risk of nephrotic syndrome development. Conclusion. Circulating amyloid precursor concentrations can be used in monitoring of disease progression.
Conclusion: plasma level measurement of amyloide’s proteins-predecessors can be used for amyloidosis diagnostic and prognosis of outcomes.

Similar Articles

Бионика Медиа